Description: A Phase I-II, First –in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies
Target Patient Population: . Currently only open for gastric cancer.
Study Design: Drug is given IV every 2 weeks